Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, IRD, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, Place Jussieu, 75005, Paris, France; Nanobacterie SARL, 36 boulevard Flandrin, 75116, Paris, France; Institute of Anatomy, UZH University of Zurich, Institute of Anatomy, Winterthurerstr. 190, CH-8057, Zurich, Switzerland.
Drug Discov Today. 2020 Jan;25(1):141-149. doi: 10.1016/j.drudis.2019.09.020. Epub 2019 Oct 3.
In nanomedicine, iron oxide nanoparticles are at an advanced stage, being commercialized for cancer treatment and iron-deficiency anemia treatment. Their therapeutic efficacy comes from their ability to target a tissue, activate a drug, locally produce a temperature increase following (or not) the application of an external source of energy, modify genes or activate various biological materials, or replace diseased cells by stem cells. Owing to these various mechanisms of action, they can potentially be used for treating a whole range of different diseases, making them more appealing than conventional drugs that target a more limited number of indications.
在纳米医学中,氧化铁纳米颗粒已经处于先进阶段,正在商业化用于癌症治疗和缺铁性贫血治疗。它们的治疗效果来自于它们靶向组织、激活药物、在应用外部能源后(或不)局部产生温度升高、修饰基因或激活各种生物材料、或用干细胞替代病变细胞的能力。由于这些不同的作用机制,它们可能被用于治疗一系列不同的疾病,这使得它们比传统药物更有吸引力,因为传统药物的作用靶点数量有限。